ECS Botanics HoldingsASX:ECS -11.11% Pretax Margin % is 0.36% as of Dec. 2025. The stock has 9 warning signs investors should review. Among 955 Drug Manufacturers companies, ECS Botanics Holdings ranks worse than 82.72% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
ECS Botanics Holdings Pretax Margin % Related Terms
ECS Botanics Holdings Pretax Margin % Historical Data
* Premium members only.
The historical data trend for ECS Botanics Holdings's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ECS Botanics Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ECS Botanics Holdings Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ECS Botanics Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where ECS Botanics Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECS Botanics Holdings (ASX:ECS) has a Pretax Margin % of 0.36% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ECS Botanics Holdings and its competitors. According to the industry distribution chart, ECS Botanics Holdings ranks #790 out of 955 companies in the Drug Manufacturers industry, placing it in the top 82.7%.
Is ECS Botanics Holdings' Pretax Margin % too high?
ECS Botanics Holdings' current Pretax Margin % is 0.36%. The Drug Manufacturers industry median Pretax Margin % is 7.28. ECS Botanics Holdings' value of 0.36% is 95.1% below this industry median. Based on the distribution chart, ECS Botanics Holdings ranks #790 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does ECS Botanics Holdings' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ECS Botanics Holdings ranks #790 out of 955 companies for Pretax Margin %. This places ECS Botanics Holdings in the lower half of its industry. The industry median Pretax Margin % is 7.28. ECS Botanics Holdings' value of 0.36% is 95.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ECS Botanics Holdings's current Pretax Margin % of 0.36% is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on ECS Botanics Holdings and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ECS Botanics Holdings's current Pretax Margin % is 0.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
Based on GuruFocus' analysis, ECS Botanics Holdings (ASX:ECS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Pretax Margin % is 0.36% and 95.1% below the Drug Manufacturers industry median of 7.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current Pretax Margin % is 0.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ECS has been successfully added to your 